How has PTC Therapeutics's interest income (expense), nonoperating changed year-over-year?

PTC Therapeutics's interest income (expense), nonoperating decreased by 43.8% year-over-year, from -$34.09M to -$49.03M.

What is the long-term trend for PTC Therapeutics's interest income (expense), nonoperating?

Over 4 years (2021 to 2025), PTC Therapeutics's interest income (expense), nonoperating has grown at a 15.3% compound annual growth rate (CAGR), from -$86.02M to -$152.23M.

PTC Therapeutics PTCT Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

NikeNKE

$15M-16.7%

Delta Air LinesDAL

-$151M+15.6%

Jaguar Uranium JAGU

$58.36K+53,151%

CencoraCOR

-$140.46M-35.1%

BlockXYZ

-$53.2M-209%

KrogerKR

-$146M-69.8%

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's interest income (expense), nonoperating?: PTC Therapeutics (PTCT) reported interest income (expense), nonoperating of -$49.03M in Q1 2026.
How has PTC Therapeutics's interest income (expense), nonoperating changed year-over-year?: PTC Therapeutics's interest income (expense), nonoperating decreased by 43.8% year-over-year, from -$34.09M to -$49.03M.
What is the long-term trend for PTC Therapeutics's interest income (expense), nonoperating?: Over 4 years (2021 to 2025), PTC Therapeutics's interest income (expense), nonoperating has grown at a 15.3% compound annual growth rate (CAGR), from -$86.02M to -$152.23M.